ID   TOV-21G
AC   CVCL_3613
SY   TOV-21g; TOV21G; TOV21
DR   BTO; BTO:0005183
DR   CLO; CLO_0009385
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-11730
DR   BCRC; 60407
DR   BCRJ; 0236
DR   BioSample; SAMN02800401
DR   BioSample; SAMN03471875
DR   BioSample; SAMN10988233
DR   CCLE; TOV21G_OVARY
DR   Cell_Model_Passport; SIDM01169
DR   Cosmic; 1066220
DR   Cosmic; 1102820
DR   Cosmic; 1139221
DR   Cosmic; 1223320
DR   Cosmic; 1305319
DR   Cosmic; 1312195
DR   Cosmic; 1328069
DR   Cosmic; 1434896
DR   Cosmic; 1449932
DR   Cosmic; 1707558
DR   Cosmic; 1708383
DR   Cosmic; 2074249
DR   Cosmic-CLP; 1240222
DR   DepMap; ACH-000885
DR   GDSC; 1240222
DR   GEO; GSM289385
DR   GEO; GSM289386
DR   GEO; GSM289416
DR   GEO; GSM289417
DR   GEO; GSM313692
DR   GEO; GSM659408
DR   GEO; GSM784567
DR   GEO; GSM851945
DR   GEO; GSM887711
DR   GEO; GSM888804
DR   GEO; GSM1176285
DR   GEO; GSM1291153
DR   GEO; GSM1374965
DR   GEO; GSM1670547
DR   GEO; GSM2475008
DR   LiGeA; CCLE_476
DR   LINCS_LDP; LCL-1530
DR   PharmacoDB; TOV21G_1605_2019
DR   PRIDE; PXD000901
DR   Wikidata; Q54972808
RX   Patent=US5710038;
RX   PubMed=10949993;
RX   PubMed=11641787;
RX   PubMed=22460905;
RX   PubMed=22705003;
RX   PubMed=22710073;
RX   PubMed=23839242;
RX   PubMed=24023729;
RX   PubMed=24224046;
RX   PubMed=25230021;
RX   PubMed=25960936;
RX   PubMed=25984343;
RX   PubMed=26388441;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=28273451;
RX   PubMed=30485824;
RX   PubMed=30894373;
RX   PubMed=31068700;
WW   http://tcpaportal.org/mclp/
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: KuDOS 95 cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: OCCP ovarian cancer cell line panel.
CC   Part of: PTEN genetic alteration cell panel (ATCC TCP-1030).
CC   Doubling time: 1.5 days (PubMed=10949993); 27 hours (PubMed=25984343); 30.62 hours (https://www.synapse.org/#!Synapse:syn2347014).
CC   HLA typing: A*11:01,26:01; B*40:02,46:01; C*04:01,02:02 (PubMed=25960936).
CC   Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger).
CC   Sequence variation: KRAS p.Gly13Cys (c.37G>T) (PubMed=22705003; PubMed=24224046; PubMed=25230021; PubMed=28273451).
CC   Sequence variation: PIK3CA p.His1047Tyr (c.3139C>T) (PubMed=22705003; PubMed=24224046; PubMed=25230021; PubMed=28273451).
CC   Sequence variation: PTEN p.Leu265fs (c.795delA) (PubMed=25230021).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative phosphoproteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Genome sequenced.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0%; Native American=1.11%; East Asian, North=0.06%; East Asian, South=0%; South Asian=1.64%; European, North=59.77%; European, South=37.42% (PubMed=30894373).
ST   Source(s): ATCC; Cosmic-CLP; PubMed=22710073; PubMed=25230021; PubMed=25877200; PubMed=30485824
ST   Amelogenin: X
ST   CSF1PO: 13,15
ST   D13S317: 11,12
ST   D16S539: 10,12
ST   D18S51: 12 (PubMed=25230021; PubMed=25877200)
ST   D18S51: 12,16 (PubMed=22710073)
ST   D19S433: 14,16.2
ST   D21S11: 28,34.2
ST   D2S1338: 17
ST   D3S1358: 14,16
ST   D5S818: 12,13
ST   D7S820: 12
ST   D8S1179: 13,16
ST   FGA: 20,23
ST   Penta D: 9
ST   Penta E: 17,19 (PubMed=25230021)
ST   Penta E: 17,18 (PubMed=25877200)
ST   TH01: 7,9.3
ST   TPOX: 8,11
ST   vWA: 17
DI   NCIt; C40078; Ovarian clear cell adenocarcinoma
DI   ORDO; Orphanet_398971; Clear cell adenocarcinoma of the ovary
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   62Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 12-03-20; Version: 29
//
RX   Patent=US5710038;
RA   Mes-Masson A.-M., Provencher D.M.;
RT   "Primary cultures of normal and tumoral human ovarian epithelium.";
RL   Patent number US5710038, 20-Jan-1998.
//
RX   PubMed=10949993; DOI=10.1290/1071-2690(2000)036<0357:COFNEO>2.0.CO;2;
RA   Provencher D.M., Lounis H., Champoux L., Tetrault M., Manderson E.N.,
RA   Wang J.C., Eydoux P., Savoie R., Tonin P.N., Mes-Masson A.-M.;
RT   "Characterization of four novel epithelial ovarian cancer cell
RT   lines.";
RL   In Vitro Cell. Dev. Biol. Anim. 36:357-361(2000).
//
RX   PubMed=11641787; DOI=10.1038/sj.onc.1204804;
RA   Tonin P.N., Hudson T.J., Rodier F., Bossolasco M., Lee P.D., Novak J.,
RA   Manderson E.N., Provencher D.M., Mes-Masson A.-M.;
RT   "Microarray analysis of gene expression mirrors the biology of an
RT   ovarian cancer model.";
RL   Oncogene 20:6617-6626(2001).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22705003; DOI=10.1016/j.humpath.2012.03.011;
RA   Rahman M., Nakayama K., Rahman M.T., Nakayama N., Ishikawa M.,
RA   Katagiri A., Iida K., Nakayama S., Otsuki Y., Shih I.-M.,
RA   Miyazaki K.;
RT   "Clinicopathologic and biological analysis of PIK3CA mutation in
RT   ovarian clear cell carcinoma.";
RL   Hum. Pathol. 43:2197-2206(2012).
//
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017;
RA   Korch C., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K.,
RA   Lessey B.A., Jordan V.C., Bradford A.P.;
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
//
RX   PubMed=23839242; DOI=10.1038/ncomms3126;
RA   Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.;
RT   "Evaluating cell lines as tumour models by comparison of genomic
RT   profiles.";
RL   Nat. Commun. 4:2126-2126(2013).
//
RX   PubMed=24023729; DOI=10.1371/journal.pone.0072162;
RA   Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M.,
RA   Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R.,
RA   Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.;
RT   "Type-specific cell line models for type-specific ovarian cancer
RT   research.";
RL   PLoS ONE 8:E72162-E72162(2013).
//
RX   PubMed=24224046; DOI=10.1371/journal.pone.0080229;
RA   Zanaruddin S.N., Yee P.S., Hor S.Y., Kong Y.H., Ghani W.M.,
RA   Mustafa W.M., Zain R.B., Prime S.S., Rahman Z.A., Cheong S.-C.;
RT   "Common oncogenic mutations are infrequent in oral squamous cell
RT   carcinoma of Asian origin.";
RL   PLoS ONE 8:E80229-E80229(2013).
//
RX   PubMed=25230021; DOI=10.1371/journal.pone.0103988;
RA   Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M.,
RA   Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J.,
RA   Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J.,
RA   Helleman J.;
RT   "Ovarian cancer cell line panel (OCCP): clinical importance of in
RT   vitro morphological subtypes.";
RL   PLoS ONE 9:E103988-E103988(2014).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:E954893-E954893(2014).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=26388441; DOI=10.1016/j.cell.2015.08.056;
RA   Creixell P., Schoof E.M., Simpson C.D., Longden J., Miller C.J.,
RA   Lou H.J., Perryman L., Cox T.R., Zivanovic N., Palmeri A.,
RA   Wesolowska-Andersen A., Helmer-Citterich M., Ferkinghoff-Borg J.,
RA   Itamochi H., Bodenmiller B., Erler J.T., Turk B.E., Linding R.;
RT   "Kinome-wide decoding of network-attacking mutations rewiring cancer
RT   signaling.";
RL   Cell 163:202-217(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P.,
RA   Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028;
RA   Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J.,
RA   Paterson J., Sircoulomb F., Krzyzanowski P., Novak M., Doodnauth S.A.,
RA   Saiz F.S., Cullis J., Al-Awar R., Neel B.G., McPherson J., Drapkin R.,
RA   Ailles L., Mes-Massons A.-M., Rottapel R.;
RT   "Interrogation of functional cell-surface markers identifies CD151
RT   dependency in high-grade serous ovarian cancer.";
RL   Cell Rep. 18:2343-2358(2017).
//
RX   PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096;
RA   Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M.,
RA   Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R.,
RA   Press M.F., Drapkin R., Easwaran H., Baylin S.B., Slamon D.,
RA   Velculescu V.E., Scharpf R.B.;
RT   "Integrated genomic, epigenomic, and expression analyses of ovarian
RT   cancer cell lines.";
RL   Cell Rep. 25:2617-2633(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//